Note: This study was funded by Merck & Co. Inc. The study protocol was the responsibility of Merck & Co. Inc. and designed in collaboration with the scientific advisory committee comprised of the academic authors and approved by various health authorities. All analyses were conducted by scientists at Merck & Co. Inc. All authors had full access to the study data and vouch for the completeness of the data set and the performance of the data analyses. This study was registered with clinicaltrials.gov identifier: with registration number NCT01453725.
Excerpted and adapted from
Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, 16-week study of subcutaneous golimumab in active non-radiographic axial spondyloarthritis patients. Arthritis Rheumatol. 2015 Sep;67(10).
